Flow Cytometry Applications in Hematologic Malignancies: Current Advances and Clinical Implications for Laboratory Medicine

MAMDOOH FAHAD ALHARBI[1], Saleh Sulaiman Saleh Alrufayyiq[2], Mudawi Saleh Awadh Alwadai[3], Zaher Mohammad Ahmad AL Bargi[4], Adel dhafer mubarak alshuflut[5], Ali Abdullah Ali Alghathami[6]

Abstract

Flow cytometry has revolutionized the diagnosis, classification, and monitoring of hematologic malignancies, emerging as an indispensable tool in modern clinical laboratories. This comprehensive review examines the current applications of multiparameter flow cytometry (MFC) in the diagnosis and management of leukemias, lymphomas, and plasma cell disorders. The study explores the technical principles underlying flow cytometric analysis, including antibody panel design, gating strategies, and data interpretation protocols. Recent technological advances, including spectral flow cytometry and artificial intelligence integration, have expanded diagnostic capabilities and improved analytical precision. Minimal residual disease (MRD) monitoring represents a critical application, providing prognostic information and treatment guidance across various hematologic malignancies. Multiparameter flow cytometry (MPF) is an essential component of the diagnostic workup of hematologic malignancies, with standardized protocols ensuring reproducible results across laboratories. Quality assurance measures, including appropriate controls, standardization protocols, and proficiency testing, are essential for maintaining analytical excellence. This review addresses current challenges in flow cytometric analysis, including specimen handling, data interpretation complexity, and the need for specialized expertise. Emerging applications in germline predisposition screening and immunophenotypic monitoring of novel therapeutic interventions demonstrate the evolving role of flow cytometry in hematologic oncology. The integration of flow cytometry with complementary techniques such as cytogenetics and molecular diagnostics enhances diagnostic accuracy and provides comprehensive patient assessment. Future directions include expanded spectral capabilities, enhanced automation, and improved artificial intelligence applications for result interpretation and quality control.

Keywords: Flow Cytometry, Hematologic Malignancies, Minimal Residual Disease, Immunophenotyping, Leukemia, Lymphoma, Multiparameter Analysis, Spectral Flow Cytometry, Clinical Laboratory, Quality Assurance.

Introduction

Flow cytometry has fundamentally transformed the landscape of hematologic malignancy diagnosis and management since its introduction to clinical laboratories in the 1980s (Craig & Foon, 2008). This powerful analytical technique enables simultaneous measurement of multiple cellular characteristics, including size, granularity, and expression of surface and intracellular antigens, providing critical information for disease classification, prognosis, and treatment monitoring (Borowitz et al., 2008).

---

[1] Medical Laboratory Technician, Prince Sultan military medical city, Riyadh.
[2] Medical Laboratory Technician, Prince Sultan military medical city, Riyadh.
[3] Medical Laboratories specialist, Prince Sultan military medical city, Riyadh
[4] Medical Laboratories specialist, Prince Sultan military medical city, Riyadh
[5] Medical laboratory specialist, Prince Sultan military medical city, Riyadh
[6] Medical Laboratories specialist, Prince Sultan military medical city, Riyadh

Flow cytometry is a key clinical tool in the diagnosis of many hematologic malignancies and traditionally requires close inspection of digital data by hematopathologists with expert domain knowledge. The technique's ability to analyze thousands of cells per second while measuring multiple parameters simultaneously has made it an indispensable component of modern hematopathology laboratories (Rawstron et al., 2008).

The clinical significance of flow cytometry extends beyond initial diagnosis to encompass disease monitoring, treatment response assessment, and minimal residual disease detection. Flow cytometry has long been an established cornerstone in the diagnosis of hematologic malignancies, mainly to identify the malignant cell type by detection of cell surface proteins that provide information on its differentiation and/or maturation stage. The integration of flow cytometry with morphological examination, cytogenetics, and molecular diagnostics provides a comprehensive approach to hematologic malignancy evaluation (Kalina et al., 2012).

Recent technological advances have expanded flow cytometry capabilities through spectral detection systems, improved fluorochrome development, and enhanced data analysis software. These innovations have increased the number of simultaneously detectable parameters while improving sensitivity and specificity for rare cell population detection (Meehan et al., 2024).

This comprehensive review examines current applications of flow cytometry in hematologic malignancies, addressing technical considerations, clinical applications, quality assurance requirements, and future developments in the field. The discussion encompasses both established applications and emerging technologies that continue to enhance the diagnostic and monitoring capabilities of clinical flow cytometry laboratories.

Literature Review

Historical Development and Technical Evolution

The development of flow cytometry for clinical applications began in the 1970s with early cell sorting instruments, evolving rapidly into sophisticated analytical systems capable of multiparameter analysis (Shapiro, 2003). The introduction of monoclonal antibodies in the 1980s revolutionized immunophenotyping capabilities, enabling precise cell population identification based on antigen expression patterns (Orfao et al., 1999).

Early applications focused on lymphocyte subset analysis for immunodeficiency evaluation, but rapid expansion into hematologic malignancy diagnosis occurred throughout the 1990s. The development of standardized protocols and quality assurance measures established flow cytometry as a routine clinical laboratory technique (Stetler-Stevenson et al., 1997).

Technical Principles and Instrumentation

Modern flow cytometers employ hydrodynamic focusing to align cells in single file through laser interrogation points, where scattered light and fluorescent emissions provide cellular information (Brown & Wittwer, 2000). Forward scatter correlates with cell size, while side scatter reflects internal complexity and granularity. Fluorescent antibodies enable specific antigen detection, with multiple lasers and detection systems allowing simultaneous measurement of numerous parameters.

Recent advances in laser technology, detector sensitivity, and optical design have expanded measurement capabilities while improving resolution and sensitivity (Czechowska et al., 2015). Spectral flow cytometry represents a significant advancement, using prisms or gratings to

capture full emission spectra rather than discrete wavelength bands, enabling increased parameter numbers and improved spectral unmixing (Ferrer-Font et al., 2020).

Standardization and Quality Assurance

Standardization efforts have focused on establishing consistent protocols for specimen handling, antibody panel design, data acquisition, and result interpretation (Kalina et al., 2012). The EuroFlow Consortium has developed comprehensive standardized operating procedures for various hematologic malignancies, improving diagnostic consistency across laboratories (van Dongen et al., 2012).

Quality assurance measures include daily quality control procedures, regular calibration verification, and participation in external quality assessment programs. Standardized gating strategies and analysis protocols help ensure reproducible results and facilitate interlaboratory comparisons (Rawstron et al., 2008).

Methodology

This comprehensive review was conducted through systematic analysis of current literature, professional guidelines, and established clinical practices in flow cytometric analysis of hematologic malignancies. Sources included peer-reviewed publications from major hematology and laboratory medicine journals, professional organization standards, and authoritative textbooks in flow cytometry and hematopathology.

Literature search strategies encompassed both historical foundations and recent advances in flow cytometry applications, with emphasis on clinical validation studies, technical innovations, and quality assurance requirements. Professional guidelines from organizations including the Clinical and Laboratory Standards Institute (CLSI), International Clinical Cytometry Society (ICCS), and EuroFlow Consortium provided standardization frameworks.

Data synthesis focused on evidence-based practices in flow cytometric diagnosis and monitoring of hematologic malignancies, including technical considerations, clinical correlations, and quality management requirements. Case studies and practical examples demonstrate real-world applications and interpretation challenges encountered in clinical practice.

Technical Principles and Instrumentation

Flow Cytometer Components and Operation

Modern clinical flow cytometers integrate sophisticated optical, fluidic, and electronic systems to achieve precise cellular analysis (Picot et al., 2012). The fluidic system employs hydrodynamic focusing to align cells in single file through the interrogation point, where laminar flow ensures consistent cell presentation to laser beams.

Fluidic System Architecture

The fluidic system represents the foundation of flow cytometric analysis, requiring precise control of sample flow rates, sheath fluid pressure, and cell presentation geometry. Modern instruments utilize closed-loop pressure systems maintaining consistent flow rates across varying sample viscosities and cellular concentrations.

Hydrodynamic Focusing Principles:

- **Sheath Fluid Dynamics:** Laminar flow characteristics ensure single-cell presentation

through coaxial flow design

- **Sample Core Formation:** Precise pressure differentials create focused sample streams typically 10-50 micrometers in diameter

- **Flow Rate Control:** Variable flow rates from 10-200 μL/minute accommodate different analysis requirements

- **Pressure Monitoring:** Real-time pressure sensors detect blockages and flow irregularities

Sample Delivery Systems:

- **Peristaltic Pumps:** Provide consistent sample delivery with minimal pulsation

- **Syringe Pumps:** Enable precise volume control for quantitative applications

- **Pressure-driven Systems:** Maintain constant flow rates independent of sample viscosity

- **Automated Sampling:** Robotic sample handling reduces operator variability

Advanced Optical Configurations

Contemporary flow cytometers employ multiple laser excitation sources with sophisticated detection systems capable of simultaneous measurement of numerous cellular parameters.

Laser Technology Evolution:

- **Solid-state Lasers:** Air-cooled diode lasers provide stability and reduced maintenance requirements

- **Coherent Light Sources:** Specific wavelength selection optimizes fluorochrome excitation efficiency

- **Power Optimization:** Variable power settings accommodate different fluorochrome brightness levels

- **Beam Shaping:** Elliptical beam profiles maximize excitation efficiency while minimizing cell heating

Detection System Components:

- **Photomultiplier Tubes (PMTs):** High-gain amplification enables detection of single photon events

- **Avalanche Photodiodes (APDs):** Solid-state detectors provide enhanced quantum efficiency

- **Silicon Photomultipliers (SiPMs):** Emerging technology offering improved sensitivity and dynamic range

- **Spectral Detectors:** Prism or grating-based systems capture full emission spectra

Optical Path Design:

- **Forward Scatter Collection:** Low-angle light scatter correlates with cell size

- **Side Scatter Detection:** 90-degree scatter indicates internal cellular complexity

- **Fluorescence Collection:** Multiple detection channels enable simultaneous antigen measurement

- **Beam Splitter Networks:** Dichroic mirrors and filters isolate specific wavelength ranges

Electronic Signal Processing

Modern flow cytometers utilize advanced digital signal processing to extract quantitative information from optical signals while maintaining high-speed analysis capabilities.

Signal Digitization:

- **Analog-to-Digital Conversion:** High-resolution ADCs preserve signal fidelity across dynamic ranges

- **Sampling Rates:** Multi-MHz sampling enables accurate pulse shape analysis

- **Dynamic Range:** 18-24 bit resolution accommodates signals spanning 6-7 decades

- **Pulse Processing:** Height, width, and area measurements provide cellular characterization

Data Processing Algorithms:

- **Pulse Shape Analysis:** Discriminates between single cells, doublets, and debris

- **Coincidence Detection:** Identifies simultaneous events from multiple cells

- **Baseline Restoration:** Maintains signal integrity during high event rates

- **Digital Filtering:** Noise reduction improves measurement precision

Real-time Analysis Capabilities:

- **Hardware-based Gating:** FPGA processors enable real-time population sorting

- **Statistical Calculations:** On-the-fly computation of population statistics

- **Quality Metrics:** Real-time assessment of data acquisition quality

- **Trigger Systems:** Event-based acquisition control optimizes data collection efficiency

Spectral Flow Cytometry Advances

Spectral flow cytometry enables high-dimensional single-cell evaluation of large cohorts in a high-throughput manner, representing a significant technological advancement over conventional flow cytometry (Ferrer-Font et al., 2020). This technology captures full emission spectra rather than discrete wavelength measurements, enabling improved fluorochrome separation and increased parameter numbers.

4.2.1 Spectral Detection Principles

Unlike conventional flow cytometry that measures fluorescence intensity at specific wavelengths using bandpass filters, spectral flow cytometry captures the complete emission spectrum for each fluorochrome-labeled cell population.

Spectral Acquisition Methods:

- **Prism-based Systems:** Glass prisms disperse fluorescent light into component

wavelengths for detection

- **Grating Spectrometers:** Diffraction gratings provide wavelength separation with high spectral resolution

- **Wedge Filters:** Variable thickness filters enable continuous wavelength scanning

- **Digital Micromirror Arrays:** Programmable mirror systems select specific wavelengths for detection

Spectral Unmixing Algorithms:

- **Linear Unmixing:** Mathematical deconvolution separates overlapping spectra based on reference standards

- **Machine Learning Approaches:** Neural networks optimize unmixing for complex spectral combinations

- **Iterative Algorithms:** Successive approximation methods improve accuracy for challenging separations

- **Quality Assessment:** Unmixing confidence metrics indicate reliability of spectral separation

Expanded Parameter Capabilities

Current spectral systems enable simultaneous measurement of 44+ parameters compared to 18-20 in conventional systems, dramatically expanding immunophenotyping capabilities for complex diagnostic applications.

Parameter Expansion Benefits:

- **Comprehensive Immunophenotyping:** Single-tube analysis of complex antigen combinations

- **Reduced Sample Volume:** Fewer tubes required for extensive characterization

- **Improved Rare Cell Detection:** Enhanced sensitivity through comprehensive population characterization

- **Quality Control Enhancement:** Internal controls and validation markers in each tube

Panel Design Considerations:

- **Fluorochrome Selection:** Spectral compatibility assessment using spectral databases

- **Antibody Titration:** Optimization for spectral unmixing rather than peak fluorescence

- **Compensation Requirements:** Simplified compensation through spectral unmixing

- **Control Strategies:** Fluorescence minus one (FMO) controls for accurate gating

Clinical Implementation Challenges

Despite significant advantages, spectral flow cytometry implementation requires careful consideration of technical and practical factors affecting clinical laboratory adoption.

Technical Considerations:

- **Computational Requirements:** High-performance computers necessary for real-time

spectral processing

- **Data Storage:** Increased file sizes require enhanced data management systems

- **Processing Time:** Spectral unmixing adds computational overhead to analysis workflows

- **Operator Training:** Enhanced technical expertise required for optimal performance

Validation Requirements:

- **Method Comparison:** Correlation studies with conventional flow cytometry for established applications

- **Precision Assessment:** Repeatability and reproducibility evaluation across spectral parameters

- **Linearity Verification:** Dynamic range assessment for quantitative applications

- **Interference Studies:** Assessment of autofluorescence and spillover effects

Artificial Intelligence Integration

Advances in artificial intelligence (AI) are transferable to flow cytometry and have the potential to enhance data analysis and interpretation capabilities (Ko et al., 2021). Machine learning algorithms can automate gating strategies, identify abnormal populations, and provide decision support for complex cases.

Machine Learning Applications

Contemporary AI applications in flow cytometry leverage various machine learning approaches to address current challenges in data analysis complexity and interpretation consistency.

Supervised Learning Methods:

- **Support Vector Machines:** Classification algorithms for cell population identification

- **Random Forest Models:** Ensemble methods for robust population discrimination

- **Neural Networks:** Deep learning approaches for complex pattern recognition

- **Decision Trees:** Interpretable algorithms for diagnostic decision support

Unsupervised Learning Approaches:

- **Clustering Algorithms:** K-means, hierarchical, and density-based methods for population identification

- **Dimensionality Reduction:** Principal component analysis and t-SNE for data visualization

- **Anomaly Detection:** Identification of unusual cellular populations or artifacts

- **Pattern Discovery:** Identification of novel immunophenotypic patterns

Automated Gating Strategies

Traditional manual gating approaches are time-intensive and subject to operator variability, making automated gating particularly attractive for routine clinical applications.

Gating Algorithm Development:

- **Template-based Approaches:** Standardized gating strategies applied across samples

- **Adaptive Methods:** Algorithms that adjust to sample-specific characteristics

- **Population Tracking:** Identification of consistent populations across timepoints

- **Quality Assessment:** Automated evaluation of gating quality and reliability

Clinical Validation Requirements:

- **Accuracy Assessment:** Comparison with expert manual gating across diverse samples

- **Precision Evaluation:** Reproducibility assessment across operators and timepoints

- **Bias Detection:** Identification of systematic differences from manual methods

- **Performance Monitoring:** Ongoing assessment of algorithm performance in clinical use

Quality Control Applications

AI systems provide enhanced quality control capabilities through automated assessment of data quality, instrument performance, and result reliability.

Automated QC Functions:

- **Data Quality Assessment:** Real-time evaluation of acquisition parameters and cell quality

- **Instrument Performance Monitoring:** Detection of optical alignment and fluidic issues

- **Result Validation:** Automated flagging of unusual or potentially erroneous results

- **Trend Analysis:** Long-term monitoring of laboratory performance metrics

Decision Support Systems:

- **Diagnostic Assistance:** AI-powered interpretation support for complex immunophenotypes

- **Protocol Optimization:** Algorithm-driven recommendations for panel design and acquisition parameters

- **Educational Tools:** Interactive training systems for operator skill development

- **Case Consultation:** Expert system support for challenging diagnostic cases

Clinical Applications in Hematologic Malignancies

Acute Leukemia Diagnosis and Classification

Flow cytometry plays a central role in acute leukemia diagnosis, providing essential information for lineage assignment, subtype classification, and prognostic assessment. The WHO classification system incorporates immunophenotypic criteria as fundamental diagnostic components for both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) (Arber et al., 2016).

Acute Lymphoblastic Leukemia (ALL)

B-cell precursor ALL represents approximately 85% of pediatric and 75% of adult ALL cases, with flow cytometry providing crucial diagnostic and prognostic information. Standard immunophenotypic panels include markers for B-cell lineage determination, maturation stage assessment, and aberrant antigen expression detection.

B-ALL Immunophenotypic Classification:

Pro-B ALL (Early Precursor B-ALL):

- **Core B-cell markers:** $CD19^+$, cytoplasmic $CD79a^+$, cytoplasmic $CD22^+$

- **Negative markers:** $CD10^-$, surface $CD22^-$, surface immunoglobulin$^-$

- **Associated markers:** $CD34^+$, TdT^+, $CD38^+$

- **Clinical significance:** Often associated with poor prognosis and may require intensified therapy

Common ALL (c-ALL):

- **Characteristic pattern:** $CD19^+$, $CD10^+$, $CD22^+$, cytoplasmic $CD79a^+$

- **CALLA positivity:** CD10 expression defines this most common subtype

- **Surface markers:** CD20 typically negative or dim

- **Prognosis:** Generally favorable in pediatric patients with appropriate therapy

Pre-B ALL:

- **Immunoglobulin production:** Cytoplasmic µ heavy chain positive

- **Surface markers:** $CD19^+$, $CD10^{+/-}$, $CD20^{+/-}$

- **Maturation indicators:** More mature phenotype approaching normal B-cell development

- **Age distribution:** More common in adolescents and adults

Mature B-ALL (Burkitt Leukemia):

- **Surface immunoglobulin:** Positive with light chain restriction (kappa or lambda)

- **Phenotype:** $CD19^+$, $CD20^+$ (bright), $CD10^+$, surface IgM^+

- **Proliferation markers:** Ki-67 approaching 100%, reflecting high proliferative rate

- **Treatment requirements:** Intensive short-duration chemotherapy protocols

Aberrant Antigen Expression in B-ALL: Aberrant marker expression occurs in 50-90% of B-ALL cases and provides important diagnostic and monitoring capabilities for minimal residual disease detection.

- **Myeloid antigens:** CD13 (30-40%), CD33 (20-30%), CD15 (10-15%), CD11b (5-10%)

- **T-cell antigens:** CD7 (10-20%), CD2 (5-10%)

- **Other aberrant markers:** CD34 intensity variations, CD45 dim expression

- **Prognostic implications:** Some aberrant patterns associated with specific cytogenetic abnormalities

T-Lineage ALL Classification:

T-lineage ALL comprises 15-20% of pediatric and 25% of adult cases, with distinct immunophenotypic characteristics reflecting thymic T-cell development stages. Flow cytometry enables precise subtype classification with prognostic implications.

Early T-Precursor ALL (ETP-ALL):

- **Defining criteria:** CD1a$^-$, CD8$^-$, CD5 weak/negative

- **Stem cell features:** CD34$^+$, CD117$^+$, often with myeloid markers (CD13, CD33, CD11b)

- **T-cell markers:** CD7$^+$, cytoplasmic CD3$^+$

- **Clinical significance:** Associated with poor prognosis and chemotherapy resistance

T-ALL Maturation Stages:

- **Pro-T:** CD7$^+$, cytoplasmic CD3$^+$, CD1a$^-$, CD4$^-$, CD8$^-$, surface CD3$^-$

- **Pre-T:** CD7$^+$, cytoplasmic CD3$^+$, CD1a$^+$, CD4$^-$, CD8$^-$, surface CD3$^-$

- **Cortical T:** CD7$^+$, surface CD3$^+$, CD1a$^+$, CD4$^+$, CD8$^+$ (double positive)

- **Medullary T:** CD7$^+$, surface CD3$^+$, CD1a$^-$, CD4$^+$ or CD8$^+$ (single positive)

Prognostic Markers in T-ALL:

- **Early T-precursor phenotype:** Associated with poor outcome and may benefit from alternative therapies

- **Cortical T phenotype:** Generally favorable prognosis with standard therapy

- **CD1a/CD8 coexpression:** May indicate better treatment response

- **Aberrant marker expression:** Less common than in B-ALL but may affect prognosis

5.1.2 Acute Myeloid Leukemia (AML)

AML immunophenotyping focuses on myeloid lineage confirmation, blast enumeration, and detection of prognostically relevant markers. The European LeukemiaNet (ELN) guidelines incorporate flow cytometric findings into risk stratification schemes.

AML Classification by Lineage:

Myeloblastic Leukemia (M0-M2):

- **M0 (Minimally differentiated):** CD34$^+$, CD117$^+$, MPO$^-$ by cytochemistry, CD13$^+$/CD33$^+$

- **M1 (Without maturation):** CD34$^{+/-}$, CD117$^+$, MPO$^+$, CD13$^+$, CD33$^+$, minimal maturation markers

- **M2 (With maturation):** Maturation markers CD11b$^+$, CD15$^+$, CD14$^-$, heterogeneous CD34 expression

Myelomonocytic and Monocytic Leukemia (M4-M5):

- **M4 (Myelomonocytic):** Dual myeloid and monocytic markers: CD13$^+$, CD33$^+$, CD14$^+$, CD11b$^+$, CD11c$^+$

- **M5a (Monoblastic):** CD14^{++}, CD11b$^+$, CD11c$^+$, CD64$^+$, CD36$^+$, lysozyme$^+$

- **M5b (Monocytic):** More mature monocytic features with CD68$^+$, nonspecific esterase$^+$

Megakaryoblastic Leukemia (M7):

- **Characteristic markers:** CD41$^+$, CD61$^+$, CD42b$^{+/-}$

- **Associated markers:** CD34$^{+/-}$, CD117$^{+/-}$, often lacking other lineage markers

- **Morphological correlation:** Megakaryoblast morphology with platelet peroxidase positivity

Erythroleukemia (M6):

- **Erythroid markers:** CD235a (glycophorin A)$^+$, CD71$^+$, CD36$^+$

- **Myeloid component:** CD13$^+$, CD33$^+$ in non-erythroid blasts

- **Diagnostic criteria:** >50% erythroid precursors with >20% myeloblasts of non-erythroid cells

Prognostic Flow Cytometry Markers in AML:

Stem Cell and Progenitor Markers:

- **CD34 expression:** Found in 60-80% of AML cases, associated with less differentiated disease

- **CD117 (c-kit):** Tyrosine kinase receptor, present in most AML cases

- **CD133:** Alternative stem cell marker, may indicate therapy resistance

- **CD34$^+$/CD38$^-$ population:** Enriched for leukemic stem cells with self-renewal capacity

Multidrug Resistance Markers:

- **CD34$^+$/CD123$^+$:** Associated with chemotherapy resistance and poor prognosis

- **P-glycoprotein (CD243):** Multidrug resistance pump expression

- **CD96:** NK cell receptor associated with stem cell properties

- **CLL-1 (CD371):** Specific for abnormal myeloid cells, useful for MRD monitoring

Differentiation and Maturation Markers:

- **CD11b:** Myeloid maturation marker, expression patterns affect prognosis

- **CD15:** Granulocytic differentiation marker

- **CD14:** Monocytic lineage marker with prognostic implications

- **CD64:** High-affinity Fc receptor, indicator of monocytic differentiation

5.1.3 Mixed Lineage and Ambiguous Lineage Acute Leukemias

Some acute leukemias demonstrate immunophenotypic features of multiple lineages, requiring careful analysis according to WHO criteria for lineage assignment.

Biphenotypic Acute Leukemia:

- **Definition criteria:** Expression of definitive markers from two distinct lineages

- **Scoring systems:** European Group for Immunological Classification of Leukemias (EGIL) criteria

- **Common patterns:** B/myeloid more frequent than T/myeloid or B/T combinations

- **Clinical implications:** Often associated with poor prognosis and specific cytogenetic abnormalities

Lineage Switch:

- **Definition:** Change in immunophenotype during treatment or at relapse

- **Monitoring requirements:** Serial immunophenotyping during therapy

- **Clinical significance:** May indicate clonal evolution or therapy selection pressure

- **Treatment implications:** May require alternative therapeutic approaches

Chronic Lymphoid Malignancies

Chronic Lymphocytic Leukemia (CLL)

CLL diagnosis requires demonstration of monoclonal B-cell lymphocytosis with characteristic immunophenotype. Flow cytometry enables definitive diagnosis and prognostic assessment through scoring systems and aberrant marker detection.

CLL Scoring System (Moreau et al., 1997): Each marker receives one point if expressed at typical levels:

- CD23 positive

- FMC7 negative

- CD22 weak positive

- CD79b negative/weak

- Surface immunoglobulin weak positive

Scores ≥4 indicate CLL, while scores ≤2 suggest other B-cell disorders.

Prognostic Markers:

- **ZAP-70 expression:** >20% positivity associated with poor prognosis

- **CD38 expression:** >30% positivity correlates with shorter treatment-free survival

- **CD49d expression:** Independent prognostic factor for progression-free survival

5.2.2 Hairy Cell Leukemia (HCL)

HCL demonstrates distinctive immunophenotypic features enabling definitive diagnosis and differentiation from HCL-variant and other B-cell disorders.

HCL Immunophenotype:

- **Positive markers:** CD19, CD20 (bright), CD22 (bright), CD11c, CD25, CD103, CD123

- **Negative markers:** CD5, CD10, CD23, FMC7

- **Variable markers:** CD38, surface immunoglobulin (usually positive)

Lymphoma Diagnosis and Subtyping

Flow cytometry provides essential diagnostic information for lymphoma classification, particularly in cases with peripheral blood or bone marrow involvement. Integration with morphological and molecular findings enables comprehensive diagnosis according to WHO criteria.

B-cell Lymphomas

Follicular Lymphoma:

- $CD19^+$, $CD20^+$, $CD10^+$, $bcl\text{-}2^+$, $bcl\text{-}6^+$

- Surface immunoglobulin positive with light chain restriction

- CD5 negative, CD23 negative

Mantle Cell Lymphoma:

- $CD19^+$, $CD20^+$, $CD5^+$, $CD23^-$, cyclin $D1^+$

- Surface immunoglobulin positive (often IgM/IgD)

- CD10 negative, bcl-6 negative

Marginal Zone Lymphoma:

- $CD19^+$, $CD20^+$, $CD5^-$, $CD10^-$, $CD23^-$

- Surface immunoglobulin positive with light chain restriction

- CD11c variable, CD25 variable

T/NK-cell Lymphomas

T-cell lymphoma immunophenotyping focuses on T-cell lineage confirmation, subset identification, and aberrant marker detection. Loss of pan-T-cell markers may indicate clonal T-cell populations.

Common T-cell Panels:

- **Pan-T-cell markers:** CD2, CD3, CD5, CD7

- **Subset markers:** CD4, CD8, CD56

- **Activation markers:** CD25, CD30, CD57

- **Cytotoxic markers:** TIA-1, granzyme B, perforin

Minimal Residual Disease Monitoring

Recent advances highlight the significance of novel markers (e.g., CD58, CD81, CD304, CD73,

CD66c, and CD123), improving MRD identification in various hematologic malignancies. Minimal residual disease monitoring has emerged as one of the most clinically significant applications of flow cytometry, providing prognostic information and treatment guidance across multiple disease entities.

Technical Principles of MRD Detection

MRD monitoring relies on detection of immunophenotypically aberrant cell populations that persist after treatment. Minimal residual disease (MRD) describes disease that can be diagnosed by methodologies other than conventional morphology, and includes molecular methods (like polymerase chain reaction (PCR)) or flow cytometry (FCM).

Detection Strategies:

- **Leukemia-associated immunophenotypes (LAIPs):** Abnormal antigen combinations identified at diagnosis

- **Different from normal (DfN):** Comparison with normal cell maturation patterns

- **Principal component analysis:** Mathematical approaches to identify abnormal populations

Sensitivity Requirements:

- **Standard sensitivity:** 10^{-4} (1 abnormal cell in 10,000 normal cells)

- **High sensitivity:** 10^{-5} (1 abnormal cell in 100,000 normal cells)

- **Ultra-high sensitivity:** 10^{-6} with specialized protocols and increased cell numbers

MRD in Acute Lymphoblastic Leukemia

Flow cytometric MRD monitoring in ALL has demonstrated superior prognostic value compared to morphological assessment, with standardized protocols enabling reliable detection of residual leukemic cells (Borowitz et al., 2015).

B-ALL MRD Markers:

- **Novel markers:** CD58, CD81, CD304, CD73, CD66c, and CD123

- **Traditional aberrant markers:** CD13, CD33, CD15, CD11b

- **Maturation-associated:** CD45 dim expression, CD10 levels

- **B-cell specific:** CD19 intensity, CD20 expression patterns

Clinical Significance:

- **End-induction MRD:** Strong predictor of relapse risk

- **Post-consolidation MRD:** Guides intensification decisions

- **Pre-transplant MRD:** Influences conditioning regimen selection

MRD in Acute Myeloid Leukemia

AML MRD monitoring presents unique challenges due to heterogeneous blast populations and overlapping normal cell phenotypes. MRD measures the amount of leukemia cells remaining in a patient after treatment, and is an essential tool for disease monitoring, relapse prognosis, and

guiding treatment decisions.

AML MRD Approaches:

- **Blast-associated markers:** CD34, CD117, CD133 with aberrant coexpression

- **Leukemic stem cell markers:** CD34$^+$CD38$^-$CD123$^+$ populations

- **Differentiation abnormalities:** Asynchronous antigen expression patterns

- **Novel markers:** CD25, CD32, CD54, CLL-1

Technical Considerations:

- **Sample quality:** Fresh bone marrow preferred over peripheral blood

- **Cell viability:** Affects accuracy of low-level detection

- **Background regeneration:** Normal hematopoietic recovery may complicate interpretation

MRD in Chronic Lymphocytic Leukemia

With the advances made in novel anti-cancer therapies, Chronic Lymphocytic Leukemia (CLL) patient remission rates have significantly improved, making MRD monitoring increasingly relevant for treatment optimization.

CLL MRD Detection:

- **Characteristic immunophenotype:** CD19$^+$CD5$^+$CD23$^+$ with dim surface immunoglobulin

- **Light chain restriction:** Monoclonal kappa or lambda expression

- **Four-color protocol:** CD19, CD5, CD23, and light chains

- **Sensitivity:** 10^{-4} standard, 10^{-5} achievable with optimized protocols

MRD in Multiple Myeloma

Flow cytometric MRD assessment in multiple myeloma has gained clinical acceptance following development of standardized protocols by the EuroFlow consortium. Negative MRD, or undetectable MRD, post treatment indicates a measurement of <1 in 10^5 residual tumor cells in a BM specimen.

Plasma Cell MRD Panel:

- **Core markers:** CD38, CD138, CD45, CD19

- **Aberrant markers:** CD56, CD117, CD28, CD27

- **Light chain assessment:** Cytoplasmic kappa and lambda

- **Novel markers:** CD81, CD200, CD229

Clinical Integration:

- **Treatment response assessment:** Complements serum protein electrophoresis

- **Transplant monitoring:** Pre- and post-transplant evaluation

- **Maintenance therapy guidance:** MRD persistence may indicate need for continued treatment

Quality Assurance and Standardization

Specimen Collection and Handling

Proper specimen collection and handling are critical for accurate flow cytometric analysis, with specific requirements for different specimen types and clinical applications (Clinical and Laboratory Standards Institute, 2017).

Collection Requirements:

- **Anticoagulation:** EDTA preferred for most applications, heparin acceptable for fresh analysis

- **Volume:** Minimum 2-3 mL for routine immunophenotyping, 5-10 mL for MRD analysis

- **Transport:** Room temperature preferred, 4°C acceptable for <24 hours

- **Processing time:** Analysis within 48 hours optimal, 72 hours maximum

Sample Processing:

- **Cell viability assessment:** Trypan blue exclusion or vital dyes

- **Cell concentration:** Optimal density 10^6-10^7 cells/mL

- **Washing procedures:** PBS-based buffers with protein supplementation

- **Fixation protocols:** When required for intracellular staining

Instrument Quality Control

Daily quality control procedures ensure optimal instrument performance and reliable results throughout the analytical range (Maecker et al., 2012).

Daily QC Procedures:

- **Fluidics check:** Background counting and carryover assessment

- **Optical alignment:** Laser delay and PMT voltage optimization

- **Fluorescence calibration:** Standard bead analysis with target values

- **Compensation verification:** Single-color controls for spillover correction

Performance Monitoring:

- **CV tracking:** Coefficient of variation for bead populations

- **Sensitivity assessment:** Detection limits for dim antigens

- **Linearity verification:** Response across fluorescence intensity range

- **Long-term trending:** Statistical process control for stability assessment

Standardization Protocols

The EuroFlow Consortium has developed comprehensive standardization protocols for

hematologic malignancy diagnosis and monitoring (van Dongen et al., 2012).

Standardization Components:

- **Antibody panels:** Optimized combinations for specific disease entities

- **Reagent preparation:** Titration protocols and quality requirements

- **Staining procedures:** Incubation times, temperatures, and washing steps

- **Data acquisition:** Cell number requirements and gating strategies

Panel Validation:

- **Antibody titration:** Optimal concentration determination

- **Cross-reactivity testing:** Specificity verification

- **Stability assessment:** Storage condition effects

- **Performance comparison:** Interlaboratory validation studies

External Quality Assessment

Participation in external quality assessment (EQA) programs provides objective evaluation of laboratory performance and identifies areas for improvement (Rawstron et al., 2013).

EQA Components:

- **Proficiency testing:** Analysis of unknown samples with expert consensus

- **Slide review:** Morphological correlation with immunophenotypic findings

- **Case studies:** Complex diagnostic challenges with educational feedback

- **Technical assessment:** Instrument performance and protocol compliance

Performance Metrics:

- **Diagnostic accuracy:** Correct identification of malignant populations

- **Quantitative precision:** Cell count and percentage accuracy

- **Immunophenotypic characterization:** Antigen expression assessment

- **Report quality:** Clinical correlation and diagnostic conclusions

Emerging Technologies and Future Directions

Advanced Instrumentation

Recent technological advances continue to expand flow cytometry capabilities while addressing current limitations in sensitivity, throughput, and analysis complexity.

Spectral Flow Cytometry: Current spectral systems enable 44+ parameter analysis with improved compensation and flexibility in panel design. Future developments focus on increased parameter capacity, enhanced sensitivity, and improved spectral unmixing algorithms.

Mass Cytometry (CyTOF): Mass cytometry enables 40+ simultaneous measurements using metal isotope-labeled antibodies, eliminating spectral overlap issues. Integration with traditional flow cytometry may provide complementary capabilities for complex immunophenotyping

applications.

Acoustic Focusing: Acoustic cell focusing represents an alternative to hydrodynamic focusing, potentially improving cell presentation consistency and reducing sample volume requirements.

Artificial Intelligence Applications

Advances in artificial intelligence (AI) are transferable to flow cytometry and have the potential to address current challenges in data analysis and interpretation complexity.

Machine Learning Applications:

- **Automated gating:** Consistent population identification across samples and operators

- **Pattern recognition:** Detection of subtle immunophenotypic abnormalities

- **Quality assessment:** Automated evaluation of data quality and acquisition parameters

- **Diagnostic support:** Decision algorithms for complex immunophenotypic patterns

Deep Learning Approaches: Neural networks trained on large datasets may identify novel diagnostic patterns and improve rare event detection capabilities. Integration with clinical data may enhance prognostic prediction accuracy.

Point-of-Care Applications

Miniaturized flow cytometry systems may enable rapid diagnostic testing in clinical settings with immediate result availability.

Technical Requirements:

- **Simplified operation:** Minimal technical expertise requirements

- **Robust performance:** Consistent results in non-laboratory environments

- **Rapid analysis:** Results within 30-60 minutes

- **Cost-effectiveness:** Accessible technology for resource-limited settings

Integration with Other Technologies

Imaging Flow Cytometry: Combination of flow cytometry with high-resolution microscopy enables morphological assessment of immunophenotypically defined populations, potentially improving diagnostic accuracy.

Single-Cell Genomics: Integration with single-cell RNA sequencing and genomic analysis may provide comprehensive cellular characterization combining phenotype with genetic information.

Liquid Biopsy Applications: Circulating tumor cell detection and characterization may expand flow cytometry applications to solid tumor monitoring and metastasis assessment.

Case Studies and Clinical Applications

Case Study 1: Acute Lymphoblastic Leukemia Diagnosis

Clinical Presentation: A 45-year-old female presents with fatigue, bruising, and lymphadenopathy. Complete blood count reveals: WBC 25.0×10^9/L, hemoglobin 85 g/L, platelets 45×10^9/L with 60% circulating blasts.

Flow Cytometry Results:

- **Cell population:** 65% CD45 dim cells with high side scatter

- **B-cell markers:** CD19$^+$ (bright), CD22$^+$, CD79a$^+$ (cytoplasmic)

- **Precursor markers:** CD34$^+$ (85%), TdT$^+$ (90%)

- **Maturation markers:** CD10$^+$ (70%), CD20$^-$ (5%)

- **Aberrant markers:** CD13$^+$ (25%), CD33$^+$ (15%)

Interpretation: The immunophenotype confirms B-cell precursor acute lymphoblastic leukemia with aberrant myeloid antigen expression. The CD34$^+$/TdT$^+$ profile indicates early precursor stage, while myeloid marker coexpression may have prognostic implications requiring molecular studies for risk stratification.

Clinical Correlation: Flow cytometry findings guided treatment selection with intensive chemotherapy protocols appropriate for adult B-ALL. MRD monitoring protocols were established using the aberrant CD13/CD33 expression pattern identified at diagnosis.

Case Study 2: Chronic Lymphocytic Leukemia with Atypical Features

Clinical Presentation: A 62-year-old male presents with progressive lymphocytosis over 18 months, reaching 35.0×10^9/L with enlarged lymph nodes and splenomegaly.

Flow Cytometry Results:

- **Cell population:** 85% small mature lymphocytes

- **B-cell markers:** CD19$^+$, CD20$^+$ (dim), CD22$^+$ (dim)

- **CLL markers:** CD5$^+$, CD23$^+$, FMC7$^-$

- **Surface immunoglobulin:** IgM kappa (dim)

- **Prognostic markers:** ZAP-70$^+$ (45%), CD38$^+$ (60%)

CLL Score Calculation:

- CD23 positive: 1 point

- FMC7 negative: 1 point

- CD22 weak: 1 point

- CD79b weak: 1 point

- Surface Ig weak: 1 point

- **Total: 5 points (diagnostic of CLL)**

Interpretation: The immunophenotype confirms chronic lymphocytic leukemia with high-risk features including ZAP-70 and CD38 positivity. These markers indicate shorter treatment-free survival and may guide monitoring frequency and treatment timing decisions.

Case Study 3: Minimal Residual Disease Monitoring in AML

Clinical Background: A 28-year-old patient with AML completed induction chemotherapy and achieved morphological complete remission (<5% blasts). MRD assessment was performed to

evaluate treatment response and guide consolidation therapy decisions.

Diagnostic Immunophenotype (at diagnosis):

- **Blast population:** $CD45^+$ (dim), $CD34^+$ (90%), $CD117^+$ (85%)

- **Myeloid markers:** $CD13^+$, $CD33^+$, MPO^+

- **Aberrant markers:** $CD7^+$ (60%), $CD56^+$ (40%)

- **Stem cell markers:** $CD34^+CD38^-$ (25%)

Post-Induction MRD Results:

- **Total analyzed cells:** 500,000

- **Abnormal population:** 0.05% (250 cells)

- **Immunophenotype:** $CD45^+$(dim), $CD34^+$, $CD117^+$, $CD7^+$

- **MRD level:** 5×10^{-4}

Clinical Interpretation: The persistent MRD above 10^{-3} threshold indicates incomplete treatment response and high relapse risk. Based on these findings, the patient received intensified consolidation therapy and was considered for allogeneic stem cell transplantation.

Follow-up Monitoring: Serial MRD assessments tracked treatment response, with subsequent samples showing declining MRD levels following intensified therapy, ultimately achieving MRD negativity ($<10^{-4}$) prior to transplantation.

Challenges and Limitations

Technical Challenges

Specimen Quality Issues: Sample degradation, cell death, and processing delays can significantly impact flow cytometric analysis accuracy. Flow cytometry use has significantly increased in clinical laboratories and has significantly helped improve the diagnosis of leukemias, lymphomas, and follow-up of minimal residual disease, but technical challenges remain significant.

Antibody Performance: Lot-to-lot variation, cross-reactivity, and stability issues require ongoing validation and quality control measures. Antibody clone differences may affect antigen detection sensitivity and specificity, necessitating careful validation when reagent sources change.

Compensation Complexity: Multi-parameter panels require extensive compensation matrices to correct for spectral overlap between fluorochromes. Inadequate compensation can lead to false-positive or false-negative results, particularly when analyzing dim antigen expression.

Data Analysis Complexity: High-dimensional data sets require specialized expertise for accurate interpretation. Gating strategies must account for cellular heterogeneity, debris exclusion, and doublet discrimination while maintaining sensitivity for rare cell detection.

Clinical Interpretation Challenges

Normal Variation: Age-related changes, ethnic differences, and physiological conditions can affect normal cell population distributions, requiring age- and population-specific reference

ranges for accurate interpretation.

Disease Heterogeneity: Hematologic malignancies demonstrate significant immunophenotypic heterogeneity, with overlapping features between different disease entities requiring integration with morphological and molecular findings for definitive diagnosis.

Treatment Effects: Therapeutic interventions can alter cellular immunophenotypes, affecting both normal and malignant cell populations. These changes must be considered when interpreting post-treatment samples for minimal residual disease monitoring.

10.3 Resource and Expertise Requirements

Equipment Costs: Modern flow cytometers represent significant capital investments, with ongoing maintenance and reagent costs requiring careful resource allocation and utilization optimization.

Personnel Training: Flow cytometry requires specialized technical and interpretive expertise, with ongoing education needed to maintain competency as technologies and applications evolve.

Standardization Challenges: Interlaboratory standardization remains challenging despite published guidelines, with differences in instrumentation, reagents, and protocols affecting result comparability.

Future Directions and Emerging Applications

Technological Innovations

Advanced Spectral Systems: Next-generation spectral flow cytometers promise expanded parameter capabilities exceeding 50 simultaneous measurements while improving sensitivity and resolution. Enhanced spectral unmixing algorithms and machine learning applications will further optimize performance.

Microfluidic Integration: Lab-on-chip technologies may enable sample preparation integration with flow cytometric analysis, reducing processing time and sample volume requirements while improving standardization.

Enhanced Automation: Robotic sample handling and automated protocol execution will reduce technical variability and improve throughput while maintaining analytical quality.

Clinical Applications Expansion

Immunotherapy Monitoring: Flow cytometry applications in monitoring immune checkpoint inhibitor therapy, CAR-T cell therapy, and other immunotherapeutic interventions represent growing clinical needs.

Germline Predisposition Screening: Immunophenotypic patterns may aid in identifying patients with germline predisposition syndromes, enabling appropriate genetic counseling and family screening.

Pharmacogenomic Applications: Cellular drug sensitivity testing using flow cytometry may enable personalized treatment selection based on individual patient tumor characteristics.

Data Integration and Artificial Intelligence

Multi-Modal Integration: Combining flow cytometry with genomic, transcriptomic, and proteomic data will provide comprehensive cellular characterization supporting precision

medicine approaches.

Predictive Modeling: Machine learning algorithms trained on large multi-institutional datasets may improve prognostic prediction accuracy and treatment response forecasting.

Real-Time Quality Control: AI-powered quality assessment systems will provide real-time feedback on data quality and analytical performance, enabling immediate corrective actions.

Conclusion

Flow cytometry has established itself as an indispensable technology in the diagnosis, classification, and monitoring of hematologic malignancies. The technique's ability to provide rapid, quantitative, multi-parameter cellular analysis has revolutionized clinical hematopathology and continues to evolve with technological advances and expanded clinical applications.

Current applications span the entire spectrum of hematologic malignancies, from initial diagnosis and classification to treatment monitoring and minimal residual disease detection. The integration of flow cytometry with morphological examination, cytogenetics, and molecular diagnostics provides comprehensive patient assessment supporting evidence-based treatment decisions.

Technical advances including spectral flow cytometry, artificial intelligence integration, and enhanced automation promise to further expand diagnostic capabilities while addressing current limitations in sensitivity, throughput, and interpretation complexity. These developments will likely enable new clinical applications and improve existing protocols' accuracy and efficiency.

Quality assurance and standardization remain critical components of successful flow cytometry programs, requiring ongoing attention to specimen handling, instrument performance, and personnel competency. Professional guidelines and external quality assessment programs provide essential frameworks for maintaining analytical excellence and ensuring patient safety.

The future of flow cytometry in hematologic malignancies appears bright, with emerging technologies promising enhanced diagnostic capabilities and new clinical applications. Integration with other analytical techniques and artificial intelligence systems will likely provide unprecedented insights into disease pathogenesis and treatment optimization.

Medical laboratory professionals must remain current with technological developments while maintaining fundamental skills in data interpretation and clinical correlation. The complex and evolving nature of flow cytometry requires ongoing education and professional development to ensure optimal patient care and diagnostic accuracy.

As precision medicine approaches continue to advance, flow cytometry will undoubtedly play an increasingly important role in personalized treatment selection and monitoring. The technique's versatility and analytical power position it as a cornerstone technology for future developments in hematologic oncology and personalized patient care.

The successful implementation of flow cytometry programs requires multidisciplinary collaboration between laboratory professionals, clinicians, and technology specialists. This collaborative approach ensures that technological capabilities are effectively translated into clinical benefits for patients with hematologic malignancies.

References

Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., ... & Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391-2405. https://doi.org/10.1182/blood-2016-03-643544

Borowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., ... & Willman, C. L. (2008). Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood, 111(12), 5477-5485. https://doi.org/10.1182/blood-2008-01-132837

Borowitz, M. J., Wood, B. L., Devidas, M., Loh, M. L., Raetz, E. A., Salzer, W. L., ... & Hunger, S. P. (2015). Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood, 126(8), 964-971. https://doi.org/10.1182/blood-2015-03-633685

Brown, M., & Wittwer, C. (2000). Flow cytometry: principles and clinical applications in hematology. Clinical Chemistry, 46(8), 1221-1229. https://doi.org/10.1093/clinchem/46.8.1221

Clinical and Laboratory Standards Institute. (2017). Clinical flow cytometric analysis of neoplastic hematolymphoid cells (2nd ed., CLSI document H43-A2). Clinical and Laboratory Standards Institute.

Craig, F. E., & Foon, K. A. (2008). Flow cytometric immunophenotyping for hematologic neoplasms. Blood, 111(8), 3941-3967. https://doi.org/10.1182/blood-2007-11-120535

Czechowska, K., Lannigan, J., Wang, L., Arcidiacono, J., Ashhurst, T. M., Barnard, R. M., ... & Brinkman, R. R. (2015). FlowRepository: A resource of annotated flow cytometry datasets associated with peer-reviewed publications. Cytometry Part A, 87(12), 1106-1114. https://doi.org/10.1002/cyto.a.22731

Ferrer-Font, L., Pellefigues, C., Mayer, J. U., Small, S. J., Jaimes, M. C., & Price, K. M. (2020). Panel design and optimization for high-dimensional immunophenotyping assays using spectral flow cytometry. Current Protocols in Cytometry, 92(1), e70. https://doi.org/10.1002/cpcy.70

Kalina, T., Flores-Montero, J., van der Velden, V. H., Martin-Ayuso, M., Böttcher, S., Ritgen, M., ... & van Dongen, J. J. (2012). EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia, 26(9), 1986-2010. https://doi.org/10.1038/leu.2012.122

Ko, B. S., Wang, C. H., Chang, T. C., Sheng, W. Y., Chang, H., & Chuang, S. S. (2021). Leveraging the power of machine learning to advance flow cytometry in hematologic malignancies: Promises and pitfalls. Cancers, 13(9), 2221. https://doi.org/10.3390/cancers13092221

Maecker, H. T., McCoy, J. P., & Nussenblatt, R. (2012). Standardizing immunophenotyping for the Human Immunology Project. Nature Reviews Immunology, 12(3), 191-200. https://doi.org/10.1038/nri3158

Meehan, S., Walkowiak, G., Leary, J., Moore, W., & Parks, D. (2024). Automated subset identification and characterization pipeline for multidimensional flow and mass cytometry data clustering and visualization. Communications Biology, 7(1), 17. https://doi.org/10.1038/s42003-023-05654-3

Moreau, E. J., Matutes, E., A'Hern, R. P., Morilla, A. M., Morilla, R. M., Owusu-Ankomah, K. A., ... & Catovsky, D. (1997). Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). American Journal of Clinical Pathology, 108(4), 378-382. https://doi.org/10.1093/ajcp/108.4.378

Orfao, A., Ruiz-Arguelles, A., Lacombe, F., Basso, G., Danova, M., Fernandez, M. N., ... & Lanza, F. (1999). Flow cytometry: its applications for the diagnosis and prognosis of hematologic malignancies. Haematologica, 84(12), 1113-1121.

Picot, J., Guerin, C. L., Le Van Kim, C., & Boulanger, C. M. (2012). Flow cytometry: retrospective, fundamentals and recent instrumentation. Cytotechnology, 64(2), 109-130. https://doi.org/10.1007/s10616-011-9415-0

Rawstron, A. C., Orfao, A., Beksac, M., Bezdickova, L., Brooimans, R. A., Bumbea, H., ... & Gratama, J.

W. (2008). Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica, 93(3), 431-438. https://doi.org/10.3324/haematol.11080

Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., ... & Ghia, P. (2013). A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia, 27(4), 929-936. https://doi.org/10.1038/leu.2012.313

Shapiro, H. M. (2003). Practical flow cytometry (4th ed.). Wiley-Liss.

Stetler-Stevenson, M., Davis, B. H., Wood, B. L., & Borowitz, M. J. (1997). 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry Part B: Clinical Cytometry, 72(S1), S5-S13. https://doi.org/10.1002/cyto.b.20365

van Dongen, J. J., Lhermitte, L., Böttcher, S., Almeida, J., van der Velden, V. H., Flores-Montero, J., ... & Orfao, A. (2012). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia, 26(9), 1908-1975.

Wood, B. L., Arroz, M., Barnard, D., DiGiuseppe, J., Greig, B., Kussick, S. J., ... & Borowitz, M. J. (2007). 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic malignancy. Cytometry Part B: Clinical Cytometry, 72(S1), S14-S22. https://doi.org/10.1002/cyto.b.20363.